Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of August 31, 2011:
- Total issued Ordinary shares: 5,581,018,443 (25p each).
- Treasury shares held: 503,996,816.
- Total voting rights: 5,077,021,627.
No material changes to financial performance or operational status are reported in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,077,021,627) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (503,996,816) to calculate the correct denominator for interest notifications.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly earnings releases for performance data.